The information on this page applies only to the United States
Valeant entered into the dental market segment with the acquisition of OraPharma, a specialty company that develops and commercializes products that improve and maintain oral health. This is an attractive market that fits our focused investment criteria as the U.S. dental market is growing at approximately six percent annually. There are also significant opportunities for expansion outside the U.S. in this segment.
Establishing and building relationships with prescribing physicians is critical in this market and OraPharma currently has the largest specialized pharmaceutical sales force in the dental industry. We believe this market has similar characteristics to the dermatology, and eye health markets and should offer us the opportunity to cross-sell a variety of our products.
OraPharma's leading products include Arestin®, indicated as an adjunct to scaling and root planing procedures for reduction of pocket depth in patients with adult periodontitis; Ossix®, a resorbable membrane; EZWhite® Pro, a teeth-whitening solution; and Onset™, a local anesthetic.